Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MIMESIS

Financiado

Cerrado

A novel systems biology approach to develop preclinical assets from innovative d...

A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses Access to new medicines targeting unmet medical need is a challenge for both the Pharmaceutical industry and the member states of the European union. For the last decade the pharmaceutical sector has faced fundamental dilemmas: -... ver más

31/10/2018

ENYO Pharma SA

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

ENYO PHARMA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-10-31

SMEInst-03-2016-2017: Dedicated support to biotechnology...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ENYO Pharma SA

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

INNOVABALT Strengthening the research and innovation capacities of the... 5M€ Cerrado

FLUDRUGSTRATEGY Combating influenza using a novel drug strategy 2M€ Cerrado

PLATAFORMA DE DESARROLLO DE FARMACOS BASADA E... PLATAFORMA DE DESARROLLO DE FARMACOS BASADA EN LA ESTRUCTURA... 1M€ Cerrado

PID2021-123888OB-I00 REDUCCION DEL TIEMPO DE DESARROLLO DE ANTIVIRALES ORALES MED... 109K€ Cerrado

PTQ-09-02-01379 Modelos farmacocinéticos y farmacodinámicos de predicción en... 28K€ Cerrado

PICARD Disruptive GPCR Lead Discovery Platform Delivering New and S... 71K€ Cerrado

Duración del proyecto: 23 meses Fecha Inicio: 2016-11-15
Fecha Fin: 2018-10-31

Líder del proyecto

ENYO PHARMA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Access to new medicines targeting unmet medical need is a challenge for both the Pharmaceutical industry and the member states of the European union. For the last decade the pharmaceutical sector has faced fundamental dilemmas: - The average cost to develop a single drug has tripled in a decade - Patent expirations have reduced revenue from blockbuster drugs - Attrition in the drug development pipeline remains high. - The rate of innovation in pharmaceutical development is low because of a focus on a restricted number of drug target classes and emphasis on developing me-too drugs. In this context, ENYO has developed an innovative systems biology based approach inspired by viruses to identify patentable chemistries directed at new human disease targets. The feasibility of this approach has been successfully demonstrated in 2015 with the identification of 40 largely unexplored novel human targets against influenza virus, which eventually resulted in the generation of leads ready for development as a therapeutic for influenza. Project MIMESIS aims to scale-up ENYO’s systems biology approach to discover original preclinical assets against human targets not previously considered tractable to drug development in both infectious (Influenza, HRV, RSV, TB and Zika) and non-infectious disease contexts (Oncology). It will scale-up the number of drug discovery targets and the disease scope and initiate the deployment of the approach to the pharmaceutical industry at the global scale. The MIMESIS approach will develop novel starting points for the development of new drugs in diseases with unmet clinical need. It will contribute to better access to medicines which will translate into higher pharmaceutical benefit to the patients. The approach has never been used before in the pharmaceutical industry and is transferable to any human disease.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores